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A B S T R A C T
We described the use of a new chemical substance Sodium nucleinate (SN) as an immunomodulatory substance exhib-
iting antiinflammatory properties. Sodium nucleinate (SN) registrated in Russian Federation as Tamerit®, is 2-ami-
no-1,2,3,4-tetrahydrophthalazine-1,4-dione sodium salt dihydrate, derivative of well known chemical substance lumi-
nol. To comprehend the mechanisms of SN immunomodulatory activity, we examined the SN modulation of the innate
inflammatory cytokine response of human PBMC stimulated with LPS in vitro. Furthermore, we studied the immuno-
modulatory effects of SN in mice challenged with E. coli LPS in vivo to investigate a possible novel approach to therapy
of excessive inflammation that interfere with the response to endotoxin and inflammatory mediators. Our results demon-
strated that SN is an efficient inhibitor of sepsis development in mice model of LPS-induced sepsis. The changes induced by
SN include decreased mice plasma inflammatory cytokine production. Simmilary we demonstrated a decreased TNF-a,
IFN-g and IL-6 response in human LPS-stimulated PBMNCs. SN was therefore shown to be a promising inhibitor of
multiple inflammatory cytokine secretion.
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Introduction
Sodium nucleinate (SN) registrated in Russian Feder-
ation as Tamerit®, is 2-amino-1,2,3,4-tetrahydrophtha-
lazine-1,4-dione sodium salt dihydrate, derivative of well
known chemical substance luminol. SN is described in
Russian pharmacopeia as immunomodulatory substance
exhibiting antiinflammatory and antioxidative proper-
ties. Another derivative of luminol, a refined monoso-
dium 5-amino-2-3-dihydro-1-4-phthalazine dione (gala-
vit) has been also extensively studied by Russian scien-
tists due to its antiinflammatory properties. Both com-
pound were not available in EU or United States until re-
cently. Only in 2002 a first article desribing clinical
immunomodulatory properties of galavit appeared1.
In 2006 Jiang Y et al. described galavit as a poverfull
protector of neurodegeneration in mice infected with the
cytotoxic retrovirus ts1, a mutant of Moloney murine
leukemia virus2. Since the protection of infected mice
was not associated with suppressed viral replication, an
antiinflammatory/antioxidant properties of galavit was
supposed to cause the protection mechanism. The idea
was also supported from studies showing that antioxi-
dant defense mechanisms are activated in cultured astro-
cytes in response to their infection by ts1 and that as
many as half of these cells survive infection by success-
fully mobilizing these pathways3.
The immunomodulatory properties of second luminol
derivative SN has been not described in western medical
literature yet. SN consists of 2 highly active aminoph-
thalhydrazides (Figure 1). To comprehend the mecha-
nisms of SN immunomodulatory activity, we examined
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the SN modulation of the innate inflammatory cytokine
response of human PBMC stimulated with LPS in vitro.
Furthermore, we studied the immunomodulatory effects
of SN in mice challenged with E. coli LPS in vivo to in-
vestigate a possible novel approach to therapy of exces-
sive inflammation that interfere with the response to
endotoxin and inflammatory mediators4.
Materials and Methods
Reagents and preparation of LPS
Water, RPMI-1640 medium supplemented with 25
mM Hepes buffer, (all sterile, cell culture-tested and
endotoxin-tested; endotoxin level  1EU/mL), and LPS
from Escherichia coli (strain 0111:B4) were commer-
cially obtained from Sigma-Aldrich Corp., St. Louis, USA.
LPS was dissolved as 1 mg/mL stock solution in water,
further diluted in a cell culture medium and titrated in a
preliminary experiment5.
Isolation and stimulation of human PBMC
Eight healthy volunteers (age range from 20 to 55
years) with no symptoms of allergy, autoimmune dis-
eases or acute infections were included in the study.
PBMC from venous blood with EDTA were isolated by
density gradient centrifugation with Ficoll-PaqueTM. The
cells were counted by the trypan blue dye exclusion
method and cultured in the RPMI 1640 medium supple-
mented with 100 U/mL penicillin, 100 mg/mL streptomy-
cin, 2 mM L-glutamine and 10% heat-inactivated human
serum. The 1´106 cells (final culture volume of 1.5 mL)
were plated in 24-well culture plates with medium alone,
with SN alone, or together SN with LPS at 37°C in a hu-
midified atmosphere of 5% CO2 in the air. To establish
the TNF-a response to the LPS challenge, PBMCs were
incubated for 18 hours with LPS (from E. coli, 0111:B4;
Sigma, St. Louis, Missouri, USA), with a final culture
concentration of 10 ng/mL. Evaluation of the IFN-g re-
sponse was performed by simultaneous polyclonal activa-
tion by phorbol 12-myristat 13-acetate (PMA), with a fi-
nal concentration of 3.33 ng/mL, and ionomycin (IONO),
with a final concentration of 500 nM. Plates were then
incubated for 40 hours. Plates with LPS and plates with
IONO&PMA were incubated at 37°C, in a 5% CO2 atmo-
sphere and 95% humidity. The cell-free supernatants
were collected at 18 and 40 hours, respectively. Super-
natant samples as well as serum samples were stored at
-20°C before being evaluated for cytokines using com-
mercially available ELISA kits for measuring human
TNF-a, IFN-g (Pierce – Endogen, Rockford, IL, USA),
IL-6 and IL12 (R&D Systems, Minneapolis, MN, USA).
Mouse experiments
Female BALB/c mice were obtained at eight weeks of
age. Each mouse was assessed daily for weight gain, feed
intake, clinical status and behavioral changes. SN in
doses of 2, 20, 200, and 2000 ug/ mouse was injected
intraperitoneally 2 h before injection with LPS (from E.
coli, 0111:B4; Sigma, St. Louis, Missouri, USA) to study
the modulation of cytokine response to LPS. Serum sam-
ples were stored at -20°C before being evaluated for three
cytokines using commercially available ELISA. TNF-a
and IL-6 were were quantified by using the Pharmingen
protocol (Pharmingen, San Diego, USA). The concentra-
tions of IFN-g were measured using commercially avail-
able ELISA kits purchased from Thermo Scientific, USA.
Statistical analysis
Descriptive statistics were calculated for all the ob-
served parameters. Independent sample t-tests were per-
formed to asses the difference in means between the two
groups A p0.05 value was considered statistically signifi-
cant. All statistical analyses were performed using SPSS
for Windows software (version 15.0.1.1., Chicago, IL, 2007).
Results
Effect of SN on in vitro cytokine production induced
by LPS in human PBMC.
The culture conditions were established to assess the
ability of SN to modulate the LPS-induced secretion of
cytokines in human PBMC. PBMC from 8 healthy volun-
teers were stimulated with a – LPS (10 ng/mL); b – LPS
(10 ng/mL) + SN (0.16–100 mg/mL); Cytokine levels in
cell culture supernatants were measured, and a modula-
tory effect of each SN concentration on the LPS-induced
cytokine production was evaluated. As shown in Figure
2, a SN addition to LPS had a significant inhibitory effect
on the LPS-induced TNF-a (SN concentrations 10–100
mg/mL), IFN-g (SN concentrations 4–100 mg/mL), and
IL-6 (SN concentrations 10–100 mg/mL).
SN treated mice ameliorate the in vivo inflammatory
response to LPS.
In animal study we investigated whether SN can re-
duce the cytokine response and thereby improve survival
in mouse endotoxin shock. To induce lethal shock, we in-
jected 1 mg i.p. LPS/mouse corresponding to a dose of 40
mg/kg b.wt. This dose produced 60% mortality within 72
hr, which is in agreement with numerous studies in mice
using LPS at doses of 30 to 60 mg/kg i.p., which usually
result in mortality rates of >50% (Redmond et al., 1991;
Novogrodsky et al., 1994). As seen in Table 1, a single in-
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Fig. 1. Structural and Chemical Tamerit® Formula.
jection of SN 2 hr before LPS significantly reduces the
mortality of endotoxin shock from 60% to 40%.
To determine the release of inflammatory cytokines
after LPS challenge, blood (1 mL) was collected by car-
diac puncture after sternotomy in pyrogen-free, nonhe-
parinized microtubes. To minimize distress, mice were
kept under deep anesthesia breathing an enflurane/oxy-
gen mix delivered from a vaporizer over a nose cone dur-
ing these procedures and then killed. Blood in micro-
tubes was allowed to clot at room temperature and
centrifuged in a microfuge (12,000 rpm for 2 min). Sera
were transferred into Eppendorf cups and stored at
-20°C until assayed. Serum concentrations of TNF-a
and IL-12 after LPS-injection were significantly lower
in animals pretreated with Tamerit compared with con-
trols (Table 1).
Discussion
In the current study, we first demonstrated that SN is
an efficient inhibitor of sepsis development in mice mo-
del of LPS-induced sepsis. The changes induced by SN in-
clude decreased mice plasma inflammatory cytokine pro-
duction. Similarly we demonstrated a decreased TNF-a,
IFN-g and IL-6 response in human LPS-stimulated
PBMNCs. SN was therefore shown to be a promising in-
hibitor of multiple inflammatory cytokine secretion. It
was shown many times before that multiple cytokine se-
cretion may trigger or prolong a vast number of patho-
logical conditions, the inhibition of cytokine release may
therefore serve as a tool for a disease control6-8. In the
current study we demonstrated that SN is an effective
cytokine inhibitor in severe sepsis that often results with
organ dysfunction and is associated with significant mor-
bidity and mortality9. Sepsis results in a cascade of
events, including the production of pro- and anti-inflam-
matory cytokines and a shift from a Th1 to a Th2 im-
mune phenotype, as well as the induction of apoptosis of
immune effector cells5,10. The early phase of sepsis is
dominated by a hyperinflammatory state mediated by
systemic production of inflammatory cytokines, includ-
ing interleukin 1 (IL-1), interleukin 6 (IL-6), tumor ne-
































































































































































































































































































Fig. 2. The effect of SN on the LPS-induced secretion of TNF-a, IFN-g, IL-6 and IL-12 in human PBMC. PBMC (1´106 cells/mL)
were isolated from venous blood of a healthy volunteer and stimulated for 4 h with with a – LPS (10 ng/mL); b – LPS (10 ng/mL) +
SN (0.16–100 ìg/mL). Each point represents the mean cytokine concentration with SEM of 8 cultures.
TABLE 1
EFFECTS OF TAMERIT ON SURVIVAL AND BLOOD CYTOKINES IN LPS CHALLENGED MICE. EACH CYTOKINE POINT REPRESENTS
THE MEAN CYTOKINE CONCENTRATION WITH SEM OF 10 SAMPLES
Parameter Control LPS
LPS + SN, mg/mouse
2 20 200 2000
Mouse survival (72hr) 100 % 40 % 40 % 40 % 60 % 60 %
IFN-g (pg/mL) 3±2.1 21±15.3 16±12.4 14±8.6 6±4.3 4±2.1
TNF-a (pg/mL) 12±8.2 222±136.7 154±97 156±112 84±54 35±26
IL-6 (pg/mL) 40±32.4 13600±8234 11561±543 6512±3411 1874±876 1811±911
crosis factor alpha (TNF-a), and gamma interferon
(IFN-g)3,7. Althought anticytokine therapies have been
introduced in Gram-negative sepsis as a means of pre-
venting excessive immune reactions, the usefulness of
antiinflammatory strategies in sepsis in order to block
the activity of a single mediator in the cascade of immune
reactions is under discussion. Despite promising experi-
mental data, monoclonal antibodies and receptor antago-
nists neutralizing a particular inflammatory cytokine,
such as TNF-a and IL-1b, have failed so far to improve
the clinical outcome of patients with sepsis9. Therefore,
novel approaches to therapy of sepsis are being investi-
gated that interfere with the intracellular signal trans-
duction to modulate the entire cellular response to endo-
toxin and inflammatory mediators.
In this study, we investigated whether SN can reduce
the cytokine response and thereby improve survival in
mouse endotoxin shock. To induce lethal shock, we in-
jected 1 mg i.p. LPS/mouse corresponding to a dose of 40
mg/kg b.wt. This dose produced 60% mortality within 72
hr, which is in agreement with other studies in mice us-
ing LPS at doses of 30 to 60 mg/kg i.p., which usually re-
sult in mortality rates of >50%10. We found that a single
injection of SN 15 min before LPS significantly reduces
the mortality of endotoxin shock from 60% to 40%. The
mechanisms responsible for a better survival in SN trea-
ted animals, however, have not been clarified. Because
LPS is a major trigger for inflammatory cytokines, which
accounts for most of its toxic and lethal effects in vitro
and in vivo, we examined the effect of SN on the release
of TNF-a, IL-6 and IL-12 during endotoxin shock11. Our
findings demonstrate that SN usage in mouse endotoxin
shock has inhibitory effect on the release of all cytokines
measured after LPS-challenge. These are the first data
demonstrating an inhibitory effect of SN on the LPS-
-stimulated cytokine release. Because IL-6 in particular
is known to cause lethal shock in various animal models
synergistically with TNF-a the suppression of cytokines
by SN in this endotoxin model most likely is a major fac-
tor for the protection from endotoxin lethality observed
in SN-treated mice12. The reduced IL-12 release in SN-
-treated mice may further ameliorate the inflammatory
response to LPS (e.g., induction of acute phase proteins),
although IL-12 per se does not seem to be a major patho-
genic factor for endotoxin lethality13.
In conclusion, our findings imply SN as potentially
important drug inhibiting the pathogenicity of LPS by
modulating cytokine response. Further studies are war-
ranted to evaluate whether SN may serve as a novel ap-
proach to therapy of sepsis.
Abbrevations
LPS lipopolysaccharide
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DERIVAT TETRAHIDROFTALAZINA »NATRIJ NUKLEINAT« IMA SNA@NI SUPRESIVNI U^INAK
NA LPS-OM STIMULIRANE MONONUKLEARNE STANICE IN VITRO I IN VIVO
S A @ E T A K
Opisali smo upotrebu nove kemijske tvari Natrij nukleinat(SN) kao imunomodulatorne tvari koja pokazuje anti-
upalna svojstva. Natrij nukleinat(SN) registriran u Ruskoj Federaciji kao Tamerit® je 2-amino-1,2,3,4-tetrahidroftala-
zin-1,4 diion, dihidrat natrijeve soli, derivat dobro poznate tvari luminol. Da bi shvatili mehanizam SN imunomodu-
lacije, ispitali smo SN modulaciju uro|enog upalnog odgovora citokina ljudskih PBMC stimuliranih sa LPS in vitro.
Nadalje, istra`ivali smo imunomodulacijske u~inke SN kod mi{eva izlo`enih LPS-om E. Coli in vivo, da bi istra`ili
mogu}i novi pristup terapiji prekomjerne upale, koji se upli}e u odgovor endotoksina i medijatora upale. Na{i rezultati
su pokazali da je SN u~inkovit u spre~avanju sepse na mi{jem modelu LPS-om inducirane sepse. Promjene inducirane
SN-om uklju~uju smanjenje produkcije plazmatskih upalnih citokina. Sli~no smo dokazali i sni`enje TNF-á, IFN-ã i
IL-6 odgovara kod ljudskih LPS-stimuliranih PBMNC. SN je stoga prikazan kao obe}avaju}i inhibitor multiple upalne
citokinske sekrecije.
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